Does Group Health Cooperative Cover Mounjaro?
The verdict
Conditional on most plans
Group Health Cooperative (GHC, Wisconsin) covers Mounjaro for type 2 diabetes with prior authorization — the diabetes-only pattern is inferred from the near-universal insurer baseline, not from a directly retrieved GHC formulary line; verify on plan formulary. Mounjaro is not covered for weight loss under any line. The weight-loss tirzepatide is Zepbound, which has separate and often-excluded coverage.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Group Health Cooperative (GHC) using your member ID.
Key facts
Group Health Cooperative (GHC) is a member-owned Wisconsin cooperative. Its Mounjaro coverage for T2D follows the near-universal diabetes-only pattern, but drug-level tier specifics are not publicly confirmed — verify directly on plan formulary.
Group Health Cooperative, member services; composite insurer pattern per CMS/PBM baseline data
The 2026 Medicare Part D out-of-pocket cap is $2,100. Most enrollees on Mounjaro for T2D reach this cap within 2–3 months and pay $0 for the remainder of the year.
CMS.gov, Medicare Part D Redesign 2025–2026
The IRA-negotiated Medicare MFN price for tirzepatide (Mounjaro) is $245/month, effective mid-2026 for Medicare enrollees.
CMS.gov, IRA Drug Price Negotiation Program, 2026
Medicare vs. commercial coverage
Whether Group Health Cooperative (GHC) covers Mounjaro depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
GHC Medicare Part D plans cover Mounjaro for type 2 diabetes only — not weight loss — with prior authorization, per the standard Part D diabetes pattern. The 2026 Part D out-of-pocket cap is $2,100; most continuous Mounjaro users for diabetes reach it within 2–3 months and pay $0 thereafter. The IRA-negotiated Medicare MFN price of $245/month begins mid-2026. Mounjaro is NOT included in the 2026 Medicare GLP-1 Bridge ($50/month, July 1 – December 31, 2027), which covers weight-loss-approved products only (Wegovy, Foundayo, Zepbound KwikPen). The Lilly savings card is not usable by Medicare beneficiaries. Verify on the GHC Medicare Part D formulary.
Commercial / Employer
Group & marketplace plans
Commercial/Employer: GHC commercial plans cover Mounjaro for T2D with prior authorization (composite pattern — verify on GHC formulary). Not covered for off-label weight loss. ACA/Individual: diabetes only, PA; weight-loss GLP-1s are commonly excluded. Verify on plan formulary for your specific GHC ACA product. Medicaid: state-dependent; Mounjaro is covered for T2D with PA where GHC operates Medicaid contracts. Weight-loss GLP-1 use is excluded. The Lilly savings card is not available to Medicaid beneficiaries. GHC is a member-owned regional cooperative — drug-level formulary details are not publicly confirmed at the national level; always verify on the plan formulary or member services.
The 5 boxes you must tick to get approved
Commercial plans that will consider Mounjaro require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Mounjaro actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
Approximately $1,300–$1,560/month retail (WAC ~$1,080). Lilly savings card: $499/month for commercially insured patients without coverage (max $647/month, up to 13 fills, expires 12/31/2026). Not available to Medicare or Medicaid beneficiaries.
List price with no coverage — before any manufacturer savings card.
With coverage
Commercial: plan-specific cost-share not publicly confirmed — verify on GHC formulary. Lilly savings card: as low as $25/month for commercially insured patients with coverage. Medicare Part D: 25% coinsurance after deductible to the $2,100 OOP cap 2026; MFN $245/month mid-2026. Medicaid: nominal cost-share, state-dependent.
Typical monthly copay once prior authorization is approved.
Bridge program
The 2026 Medicare GLP-1 Bridge ($50/month) covers weight-loss-approved products only (Wegovy, Foundayo, Zepbound KwikPen). Mounjaro is not included.
Reduced copay through the assistance program, where eligible.
All figures are estimates; actual cost-share varies by GHC product and pharmacy. GHC is a regional cooperative — drug-level tier specifics are not publicly confirmed at the national level. Confirm tier and copay on the GHC formulary or by calling member services. The Lilly savings card applies only to commercially insured patients and expires 12/31/2026.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Look up Mounjaro on the GHC formulary
Visit ghc.org or call GHC member services and request the drug formulary for your specific plan (commercial, ACA, or Medicare Part D). Search for 'Mounjaro' or 'tirzepatide'. Confirm it is listed for type 2 diabetes (E11.x), note the tier, and check whether prior authorization is required. As a regional cooperative, GHC's drug-level coverage details may not appear on national drug-lookup tools — go directly to the plan.
- 2
Have your prescriber submit the prior authorization
Your prescriber must document your confirmed T2D diagnosis, A1c of 6.5% or higher, and prior oral agent step therapy (metformin plus typically one additional agent). Ask your prescriber's office to submit a PA request to GHC. Verify the exact PA criteria on the GHC formulary before submission, as criteria for regional cooperative plans may differ from national PBM composites.
- 3
Call GHC member services to confirm coverage and cost
Call the number on the back of your GHC card. Ask: Is Mounjaro covered for type 2 diabetes on my plan? What is my cost-share after prior authorization? Is the 2026 Medicare GLP-1 Bridge applicable to Mounjaro? (Answer: No — Mounjaro is excluded from the Bridge because it is a diabetes drug, not a weight-loss product.)
Options if Group Health Cooperative (GHC) won't cover Mounjaro
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Ozempic (semaglutide)
FDA-approved for type 2 diabetes. Often covered with PA on commercial and Medicare Part D plans; may be at a more favorable tier than Mounjaro — verify on GHC formulary.
Trulicity (dulaglutide)
FDA-approved for T2D. GLP-1 alternative with lower list price than Mounjaro; often preferred tier on regional cooperative formularies — verify on plan.
Jardiance (empagliflozin)
SGLT2 inhibitor for T2D with cardiovascular benefits. Often preferred tier; may be required as step therapy before GLP-1 approval. Verify on GHC formulary.
Zepbound (tirzepatide) — weight loss only
Same molecule as Mounjaro (tirzepatide) but FDA-approved for chronic weight management and obstructive sleep apnea — not diabetes. Has separate and often-excluded coverage; included in the 2026 Medicare GLP-1 Bridge for weight-loss-approved products. Do not substitute Mounjaro for Zepbound — they are different FDA approvals.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
No. Mounjaro is FDA-approved for type 2 diabetes only — not weight loss. No insurer, including GHC, covers Mounjaro for off-label weight loss; those requests are denied. The weight-loss version of tirzepatide is Zepbound, which has separate and often-excluded coverage. Verify Zepbound coverage separately on the GHC formulary if weight loss is your goal.
Mounjaro and Zepbound contain the same active ingredient (tirzepatide) but have different FDA approvals. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and obstructive sleep apnea. GHC follows the standard pattern: Mounjaro is coverable for diabetes with PA; Zepbound has separate coverage that must be verified on the GHC formulary.
Group Health Cooperative is a regional member-owned cooperative, and its drug-level formulary details are not publicly confirmed at the national level. The diabetes-only coverage pattern is inferred from the near-universal insurer baseline. Verify directly at ghc.org or by calling GHC member services — do not rely on national drug-lookup tools for GHC-specific tier or cost-share information.
Commercial cost-share is not publicly confirmed for GHC — verify on plan formulary. The Lilly savings card can reduce cost to as little as $25/month for commercially insured patients with coverage, or $499/month without (expires 12/31/2026; excludes Medicare and Medicaid). Medicare Part D: 25% coinsurance to the $2,100 OOP cap 2026; IRA-negotiated MFN price of $245/month begins mid-2026.
All three are Wisconsin/Upper-Midwest regional plans (GHC is member-owned cooperative; Security Health Plan is Marshfield Clinic-owned; Quartz is provider-owned) that follow the standard diabetes-only GLP-1 coverage pattern. None has publicly confirmed drug-level formulary details — all three require direct verification with the plan. The Mounjaro-for-diabetes, Zepbound-for-weight-loss distinction applies equally to all.
Related Articles
Does Quartz Health Solutions Cover Mounjaro? 2026 | Curex
Quartz Health Solutions (WI) covers Mounjaro for type 2 diabetes with prior auth — not weight loss. Composite plan; verify on Quartz formulary.
Read moreDoes Security Health Plan Cover Mounjaro? 2026 | Curex
Security Health Plan (WI) covers Mounjaro for type 2 diabetes with prior auth — not weight loss. Composite pattern; verify on plan formulary.
Read moreDoes Geisinger Health Plan Cover Mounjaro? 2026 Guide | Curex
Geisinger covers Mounjaro for type 2 diabetes with prior auth — not weight loss. PA Medicaid is diabetes-only after the 2025 weight-loss GLP-1 cut.
Read moreDoes Health Net Cover Ozempic? 2026 Coverage Guide | Curex
Health Net covers Ozempic for type 2 diabetes with prior auth — not weight loss. Medi-Cal T2D covered. Verify tier on Health Net drug lookup tool.
Read moreDoes Group Health Cooperative Cover Wegovy? 2026 | Curex
Group Health Cooperative covers Wegovy only where your employer opted in. Wisconsin co-op — drug-level detail not public. Verify on GHC's drug-lookup tool.
Read moreDoes Harvard Pilgrim Health Care Cover Mounjaro? 2026 | Curex
Harvard Pilgrim (Point32Health) covers Mounjaro for type 2 diabetes with PA — not weight loss. MA Medicaid covers diabetes; weight-loss GLP-1s restricted.
Read moreInsurance covers Mounjaro only for diabetes — for weight loss, here's a path that skips insurance
Group Health Cooperative covers Mounjaro for diabetes only, not weight loss — the weight-loss twin Zepbound is a separate, often-excluded question. For patients who want tirzepatide access without insurance, compounded tirzepatide from $149/mo (and compounded semaglutide from $49/mo) is available at getcurex.com/cl/glp — no insurance required, no prior authorization. This is compounded tirzepatide and is not the same medication as Mounjaro or Zepbound. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Mounjaro and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Group Health Cooperative (GHC) before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Mounjaro and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.